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68 Poster Session-ICD34(1) cell dose received (Table 1). Our data expand on previous
work in this area by including data in patients receiving chemother-
apy, thalidomide and bortezomib based inductions. Findings suggest
pre-mobilization marrow plasmacytosis may be a practical, effective
test to determine chances of mobilization success in patients with
prior lenalidomide exposure.
Effects of induction regimen on stem cell mobilization
Type of InductionChemotherapy Thalidomide Lenalidomide Bortezomib vp-
aluePre-mobilization
bone marrow:plasmacytosis,
successfully
mobilized (%)22 14 5 12 0.001plasmacytosis,
failed
mobilization
(%)39 21 23 0.004Apheresis
sessions
(median)2 2 3 2 0.008CD34(1) stem
cell
collection:Day 1 9.9 7.4 3.6 6.1 0.004Total 18 11 8 8 0.0001Engraftment
kinetics:ANC
. 500/uL
(days)9 10 11 10.5 0.003182
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS
AGED $65 YEARS WITH MULTIPLE MYELOMA: MOFFITT CANCER CEN-
TER EXPERIENCE
Paoletti, C.1, Balducci, L.2, Alsina, M.1, Boler, I.2, Popa, M.A.2,
Extermann, M.2, Lara-Rivera, S.2, Raychaudhury, J.1, Anasetti, C.1,
Fernandez, H.1, Sullivan, D.1, Dalton, W.S.1, Field, T.1, Ayala, E.1, Khar-
fan-Dabaja, M.A.1, Perez, L.1, Perkins, J.1, Janssen, W.E.1, Harris, J.1,
Schell, M.3, Kim, J.3, Ochoa-Bayona, J.L.1 1Moffitt Cancer Center, Tampa,
FL; 2Moffitt CancerCenter, Tampa, FL; 3Moffitt Cancer Center, Tampa, FL
ASCT has demonstrated to prolong the survival in Multiple Mye-
loma (MM) patients, but the benefit of this therapy and impact of co-
morbidities for elderly patients has not been well established. We
retrospectively analyzed MM patients aged $ 65 years who under-
went ASCT from 2001 to 2006. We examined a series of clinical pa-
rameters [e.g. age, gender, stage at diagnosis, time from diagnosis to
transplant (TDT), lines of chemotherapy before transplant, response
to first-line therapy, conditioning regimens, incidence and type of
non-hematological toxicities (NHT), and comorbidity] and clinical
outcomes [e.g. time to neutrophils and platelets engraftment, length
of hospital stay (LOS), progression-free survival (PFS), and overall
survival (OS)]. PFS and OS were calculated from the time of trans-
plant to the time of event occurrence. One-hundred and ten patients
(45 F, 65 M), median age 68 (65–77), were eligible. Two thirds had
Durie-Salmon stage III, 31% received more than 1 line of therapy,
and 27% were refractory to first-line therapy. The median TDT
was 8.8 months (2–208). The mean scores for Charlson comorbidity
index, cumulative illness rating scale for geriatrics, and Hemopoietic
Stem cell Transplantation Comorbidity Index, retrospectively calcu-
lated at time of transplant, were 0.6 (0–6), 5 (0–12), and 2 (0–7), re-
spectively. Conditioning regimens were melphalan alone (63%) or
melphalan plus other drugs (37%). The median LOS was 19 days
(0–60). Thirty-seven percent of patients did not develop any grade
4 NHT; the most common grade 4 NHT were infection, mucositis,
and supraventricular arrhythmias. The median number of days to
neutrophils .0.5  109/L and to platelets .20  109/L was 12 (6–40) and 13 (6–187), respectively. TRM at day 100 was 4.5%.Median
PFS and OS were 14.3 (12.2–20.3) and 36.7 months (28.2–45.4), re-
spectively. Multivariate analysis showed male was a significant factor
for time to neutrophil engraftment (HR5 0.64; 95%CI: 0.41–0.99).
Older age (HR 5 0.92; 95% CI: 0.85–0.99) and more toxicities
(HR 5 0.49; 95% CI: 0.38–0.63) were significant predictors for in-
creasing LOS. Longer TDT was significant (HR 5 1.02; 95% CI:
1.00–1.03) for decreasing LOS. No factor was found to be signifi-
cantly predictive for PFS and OS. Comorbidity did not predict PFS
and OS at univariate level. ASCT in MM patients aged $ 65 years
is associated with low peritransplant mortality and manageable
toxicity making it a feasible option for this patient population.183
COMBINATION OF IFN-/GM-CSF AS MAINTENANCE THERAPY FORMULTI-
PLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLAN-
TATION (ASCT): RESULTS OF A PROSPECTIVE PHASE II STUDY
Salmasinia, D., Moreb, J.S. university of Florida, Gainesville, FL
Several studies have shown that maintenance therapy with IFN-
a after ASCT prolongs response duration and may improve survival.
In our experience, up to 30% of the patients are unable to take IFN-
a because of either slow hematopoietic recovery after ASCTor IFN-
induced pancytopenia. In this study, we combined GM-CSF with
IFN-a in order to improve IFN tolerance in post-ASCT myeloma
patients. Primary aims were to evaluate toxicity, long term side ef-
fects, and effectiveness of this combination maintenance therapy.
The treatment (4  106 units of IFN-a and 125 mg/m2 of GM-
CSF) schedule was three times a week (M, W, F) for twelve months.
After that, patients would continue IFN-a at the discretion of the
treating physician. Between January 2003 and June 2007, 27 patients
were enrolled after signing informed consents within 120 days of
ASCT, and four of them had tandem ASCT. Patients with progres-
sive myeloma were excluded from study. One enrolled patient was
excluded from analysis for not taking the drugs. Only one patient dis-
continued treatment due to moderate pancytopenia and two devel-
oped skin rashes/cellulitis related to GM-CSF injections. Seven
others were taken off study due to persistent IFN-related flu-like
symptoms and/or increase in liver enzymes. Median length of treat-
ment with the combination was 11.5 months. Seven patients contin-
ued IFN-a beyond one year, four of whom are still taking it. With
a median follow-up of 44.5 months (n5 26), an intent -to-traet anal-
ysis reveals overall survival (OS) and progression-free survival (PFS)
of 51 and 45 months, respectively. Eleven patients (42%) have re-
mained in VGPR/CR since ASCT. These results were compared
to a historical group of patients (n 5 25) who had a median of 8
months IFN only treatment with PFS of 22 months. In conclusion,
our results demonstrate the effectiveness of GM-CSF in ameliorat-
ing the IFN-induced myelotoxicity and achieving better PFS.184
IMPROVED OUTCOME FOR ALLOGENEIC TRANSPLANTATION
PERFORMED AFTER JANUARY 2000
Pelosini, M., Mendoza, F., Hosing, C., Popat, U.R., Anderlini, P.,
Alousi, A.M., Kebriaei, P., Weber, D.M., Wang, M., Champlin, R.E.,
Giralt, S.A., Qazilbash, M.H. UT - MD Anderson Cancer Center,
Houston, TX
Background: Allogeneic hematopoietic stem cell transplantation
(allo SCT) is a potentially curative approach in patients withmultiple
myeloma (MM). The potential benefit is offset by a higher risk of
transplant-related mortality (TRM), graft-vs-host disease (GVHD)
and opportunistic infections. A number of factors including better
supportive care, antimicrobial agents, improvement in HLA typing
and reduced intensity conditioning (RIC) regimens have resulted in
a lower risk of TRM. We evaluated if there was an improvement in
the outcome of patients who received allo SCT forMMafter January
1, 2000 compared to patients who received allo SCTbefore that date.
Methods: 101 patients underwent allo SCT at UT-MDACC be-
tween 11/1985 and 1/2007, with 40 patients undergoing allo SCT
before January 1, 2000 (group A) and 61 after that date (group B).
Median age at allo SCT in Group A and B was 42 and 48 years,
Poster Session-I 69respectively; median number of prior regimens in both groups was 5.
Twelve patients (30%) in group A and 42 patients (69%) in group B
had a prior autologous SCT.
Results: Median follow up in surviving patients was 8.2 years in
group A and 2 years in group B. Reduced-intensity conditioning
(RIC) regimens were used in 15 patients (37%) in group A, and 56
patients (92%) in group B. Cumulative TRM in group A and B
was 57% and 31%, respectively (p 5 0.006). Disease progression
was seen in 15 patients (37.5%) in group A and in 31 patients
(50%) in group B (p 5 0.22). Time to progression from allo SCT
was 10.1 moths, with no significant difference between the 2 groups
(p5 0.85). As shown in Figures 1 and 2, patients in group B had sig-
nificantly longer PFS (7.3 vs. 4.8 months; p5 0.03, log rank test) and
OS (13.1 Months vs. 5.9 months; p5 0.008, log rank test). Grade II-
IV acute GVHD was seen in 21 patients (52%) in group A, and 21
patients (34%) in group B (p 5 0.09). Limited or extensive chronic
GVHD was seen in 15 patients (37%) in group A, and 20 patients
(32%) in group B (p 5 0.67). At the time of this analysis, 3 patients
in group A and 18 in group B were alive, while 2 patients in group A
and 12 in group B were alive and in remission.
Conclusions: Patients transplanted after January 2000 although
older and having failed a prior ASCT had significantly lower
TRM, lower incidence of acute GVHD and significantly longer
PFS and OS.185
HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANS-
PLANTATION FOR MULTIPLE MYELOMA: ACHIEVEMENT OF COMPLETE
REMISSION IS ASSOCIATED WITH IMPROVED SURVIVAL
Kumar, L., Ghosh, J., Ganessan, P., Gupta, A., Hariprasad, R. All India
Institute of Medical Sciences, New Delhi, India
We analyzed results of 108 patients of multiple myeloma who un-
derwent autologous stem cell transplantation (ASCT). Patients’ me-
dian age was 52 years (range, 26 to 68 years), M:F : 78 : 30. High
dosemelphalan (200mg/m2) was used for conditioning. 66 (61%) pa-
tients had evidence of chemo-sensitive disease prior to transplant. Fol-
lowing ASCT 79.6% of patients responded; complete (CR) - 36%,
very good partial response (VGPR) -29.6%, and partial response
(PR) -13.9%.CRratewas higher for patientswith chemo-sensitive dis-
ease; 33/66patients (50.0%) achievedCRcomparedwith7/42 patients
(14.3%) with progressive disease, p\.01. At a median follow up of 70
months , the median overall (OS) and event-free survival (EFS) is 71
and 42months, respectively . Estimated overall and event-free survival
at 60 months is 54.4%6 0.05 %(SE) and 49.3%6 0.05(SE), respec-
tively.Forpatientswithpre-transplantchemo-sensitivediseasemedian
OS (102 vs 38 months ,p\.0003) and EFS (96 vs for 21 month-
s,p\.0002) is significantly higher. Mean OS for patients with CR is
148.99 months (95% CI 116.75–181.23) (median not reached) and
for those with VGPR is 73.81 (95% CI 58.91–88.71) (median not
reached) ,p\0.04. Median OS for patients with PR, stable disease
and thosewithprogressive disease is 39, 24 and11months, respectively
(p\0.0003). Median EFS for patients with CR is 129.9 months (95%
CI 101.3–158.5) and 52.4 months (95% CI 41–63.8) for those with
VGPR ,p\.03. Median EFS for patients with PR, stable and
progressive disease is 20, 15 and 5 months respectively, p\0.0001.
Conclusion : Survival is significantly better for patients with pre-
transplant chemo-sensitive disease and those who achieve complete
remission following transplant.186
BUSULFANANDCYCLOPHOSPHAMIDEHAS SIMILAROUTCOMES TOHIGH
DOSE MELPHALAN AS A PREPARATIVE REGIMEN FOR AUTOLOGOUS
STEMCELL TRANSPLANTATION IN PATIENTSWITHMULTIPLEMYELOMA
Mahindra, A.1, Bolwell, B.1, Rybicki, L.2, Dean, R.1, Pohlman, B.1,
Sobecks, R.1, Andresen, S.1, Sweetenham, J.1, Kalaycio, M.1, Copelan, E.1
1Cleveland Clinic, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
High dose chemotherapy (HDC) with autologous stem cell trans-
plant (ASCT) has been shown to increase the rate of complete re-
sponse and prolong survival in multiple myeloma (MM). We
report a single-institution experience comparing two conditioning
regimens, busulfan (oral dose, 16mg/kg; intravenous dose 12.8mg/kg) and cyclophosphamide (120mg/kg) (BuCy) versus high dosemel-
phalan (200 mg/m2) (HDM). Between January 2000 and March
2008, 152 patients (pts) with MM underwent HDC with ASCT us-
ing either BuCy (n5 117; 73 pts (62%) received oral Bu) or HDM (n
5 35) in sequential cohorts as the preparative regimen. 61 patients
(52%) in the BuCy group and 26 patients (74%) in the HDM group
were male (p 5 0.02). The two groups were otherwise similar with
respect to age, ISS stage, b2 microglobulin, number of prior chemo-
therapy regimens, prior radiation therapy, FEV1 and DLCOc pre
transplantation. In the group receiving BuCy, 81 patients (69%)
are alive with a median follow up of 20.2 months (range, 5.3–97.5).
In the HDMgroup, 31 patients (88%) are alive with a median follow
up of 18.7 months (range, 3.8–55.4). The median relapse free sur-
vival (RFS) for patients receiving the BuCy regimen was 3.3 years
and for patients receiving HDM has not yet been observed (p 5
0.052). The median overall survival (OS) for patients receiving the
BuCy regimen was 6.1 years and for patients receiving HDM has
not been observed. Patients treated with BuCy achieved granulocyte
count .500/mL by day 10 (range, 9–13) whereas patients treated
with HDM recovered by day 13 (range, 10–17) post-transplant
(p\0.001). Patients achieved platelet counts greater than 20,000/
mL at a median of 12 days (range, 8–46) after BuCy and by 13 days
(range, 8–27) after HDM treatment (p 5 0.039). Treatment related
mortality (TRM) was documented in 7 patients (5.9%) in the BuCy
group and 2 patients (5.7%) in the HDM group. Bacteremia was
documented in 19 patients (16%) in the BuCy group and 10 patients
(28%) in the HDM group. BuCy led to faster hematopoietic recov-
ery compared to HDM. RFS, OS and TRM were similar. BuCy and
HDMconfer similar long-term outcomes with comparable toxicities
as conditioning regimens prior to ASCT in patients withMM. Stud-
ies of tandem transplantation might benefit from using busulfan
based regimen in place of a second melphalan-based regimen.187
MAINTENANCE THERAPY WITH LOW DOSE THALIDOMIDE, DEXAMETH-
ASONE, AND CLARITHROMYCIN (BIAXIN) (BLT-D) FOLLOWING AUTOL-
OGOUS TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM)
Holmberg, L.A.1,2, Bensinger, W.I.1,2 1Fred Hutchinson Cancer Research
Center, Seattle, WA; 2University of Washington School of Medicine,
Seattle, WA
Since relapse remains amajor problem after ASCT forMM, inves-
tigators have looked at the role of maintenance therapy post trans-
plant. It is not yet established as to what maintenance regimen is
best nor what is the optimal duration for therapy. M. Coleman et al
(Leukemia and Lymphoma 43: 1777, 2002) pioneered a regimen of
BLT-D to treat non-transplant MM patients, with high CR/PR
rate(93%). Thus, it seemed reasonable to study the regimen of
BLT-D as maintenance therapy after ASCT for MM. Twenty-seven
patients (stage II, n 5 8; stage III, n 5 19 by Durie-Salmon) were
treated. Before ASCT, 52% of patients received Thalidomide; 37%
received . one regimen (range 2–4) prior to chemomobilization of
PBSC. At time of ASCT, 20% of patients were in CR/nCR. All pa-
tients were conditioned with melphalan 200 mg/m2. At 30–120
days after recovery fromacute toxicity ofASCT,patientswere treated
withBiaxin 250mgpobid, dexamethasone 20mgpoweekly andTha-
lidomide beginning dose 50mg po daily forD1–14, then increased to
100mgpodaily. Aspirinwas used forDVTprevention. After one year
of combination therapy, dexamethasone and Biaxin were stopped.
Thalidomidewas continued as long as tolerated until diseaseprogres-
sion. One patient withdrew from therapy to undergo elective 2nd
ASCT.Neuropathywas themost common toxicity; 11 patients(41%)
stopped because of unimproved $ grade 2 neuropathy, median 12
months of therapy (range 6–30), and 7 patients(30%) required dose
reduction of Thalidomide. One patient stopped Thalidomide for
rash. Nine patients(33%) had dose reduction of dexamethasone.
Median time of Thalidomide therapy for all patients is 15 months
(range 3–43). The number of infections included: pneumonia (n 5
3), viral upper respiratory (n 5 2), sinusitis (n 5 1), and bronchitis
(n 5 3). As of 9/08, 22 patients(82%) remain alive, with median
follow-up of 3.54 years (range 1.98–4.19). Five patients have died
due to infection (n 5 1), MM (n 5 3), and complications of 2nd
ASCT (n5 1). Fifteen patients(56%) of 27 remain alive without dis-
ease progression,medianTTPwas 18months (range 3–39). Four pa-
tients remain on therapy at 25–43 months. In summary, BLT-D can
